• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Establishment of tailor-made treatment strategy with gefitinib against peritoneal metastasis from gastric carcinoma.

Research Project

Project/Area Number 17591388
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionNagoya University

Principal Investigator

KODERA Yasuhiro  Nagoya University, Graduate School of Medicine, Assistant Professor, 大学院・医学系研究科, 講師 (10345879)

Co-Investigator(Kenkyū-buntansha) NAKAO Akimasa  Nagoya University, Graduate School of Medicine, Professor, 大学院・医学系研究科, 教授 (70167542)
Project Period (FY) 2005 – 2006
Project Status Completed (Fiscal Year 2006)
Budget Amount *help
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2006: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2005: ¥2,000,000 (Direct Cost: ¥2,000,000)
Keywordsgastric cancer / molecular targeting / gefitinib / chemosensitivity test / PI3K pathway / MAPK pathway / apoptosis / drug resistance / 耐性株 / 抗腫瘍効果
Research Abstract

The IC50 values against gefitinib was 0.028, 0.32, 0.078, and 0.091 μ M respectively for HER2 over-expressing cell lines GLM-1, GLM-2, GLM-4, and NIC-N87 established from gastric cancer liver metastases whereas they were >10 μ M in other gastric cancer cell lines. Gefitinib also exhibited eminent antiproliferative effect against GLM-1 xenografts in vivo. Gefitinib induced apoptosis in HER2 over-expressing cells at a dose of 1 μ M. LY294002, a blocker of the PI3K pathway, also induced apoptosis whereas U016 did not, and proliferation of HER2 over-expressing cells are considered to be mediated mainly through the PI3K pathway. In GLM-1, the phosphorylation of Erkl/2 was induced by ligand stimulation, but gefitinib was found to prevent this phosphorylation. Constitutive phosphorylation of Akt without ligand stimulation was observed in all cell lines, but this autophosphorylation was blocked by gefitinib only in HER2 over-expressing cell lines.
GLM-1R, a gefitinib resistant clone of GLM-1 li … More neage, was created by exposure to low dose gefitinib. The IC50 value of GLM-1R was 1.82μ M and was 65-fold that of parental GLM-1. Constitutive phosphorylation of Akt was observed in the absence of ligand stimulation in GLM-1R to the extent observed in the parental cell line, but phosphorylation of Shc and Erkl/2 was more prominent in the resistant clone, suggesting that signal transduction through the MAPK pathway compensates for the blockage of PI3K pathway by gefitinib, thus conferring drug resistance.
Collagen gel droplet chemosensitivity test was performed with 30 fresh surgically resected specimens to test for sensitivity against gefitinib. Of three specimens found sensitive, all three were not stained for EGFR whereas two were strongly stained for HER2. In addition, of four patients with hepatic metastases, two stained positive for HER2 and were sensitive against gefitinib. Thus, a specific subgroup of gastric cancer that expresses HER2, has propensity towards liver metastasis, and is vulnerable to a treatment with gefitinib does exist. Less

Report

(3 results)
  • 2006 Annual Research Report   Final Research Report Summary
  • 2005 Annual Research Report
  • Research Products

    (6 results)

All 2007 2006

All Journal Article (6 results)

  • [Journal Article] Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer : Correlation with drug sensitivity against 5-fluorouracil2007

    • Author(s)
      Y.Kodera
    • Journal Title

      Cancer Letters (In press)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2006 Annual Research Report 2006 Final Research Report Summary
  • [Journal Article] Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer. Correlation with drug sensitivity against 5-fluorouracil2007

    • Author(s)
      Y.Kodera
    • Journal Title

      Cancer Letters (In press)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis2006

    • Author(s)
      H.Yokoyama
    • Journal Title

      British Journal of Cancer 95・11

      Pages: 1504-1513

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2006 Annual Research Report 2006 Final Research Report Summary
  • [Journal Article] In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues2006

    • Author(s)
      Y.Kodera
    • Journal Title

      International Journal of Clinical Oncology 11・6

      Pages: 449-453

    • NAID

      10020571797

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2006 Annual Research Report 2006 Final Research Report Summary
  • [Journal Article] Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis2006

    • Author(s)
      H.Yokoyama
    • Journal Title

      British Journal of Cancer 95.11

      Pages: 1504-1513

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2006 Final Research Report Summary
  • [Journal Article] In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues2006

    • Author(s)
      Y.Kodera
    • Journal Title

      International Journal of Clinical Oncology 11-6

      Pages: 449-453

    • NAID

      10020571797

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2006 Final Research Report Summary

URL: 

Published: 2005-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi